News Gilead Sciences, Inc. Mexican S.E.

Stocks

GILD *

US3755581036

Pharmaceuticals

End-of-day quote Mexican S.E. 2026-09-10			5-day change	1st Jan Change
2,453.18 ^MXN	-1.08%		0.00%	+10.39%

09-18	Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2%	MT
09-16	Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing	MT

All News

Mentions Relevance

09-18	Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF	AQ
09-16	Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing	MT
09-16	Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited	CI
09-16	Gilead Sciences Expands Licensing Agreements for HIV Treatment	MT
09-16	Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention	BU
09-15	Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean	CI
09-15	Gilead Sciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:45 AM
09-15	Gilead Sciences Expands Lenacapavir Access to 14 Countries	MT
09-15	Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean	RE
09-15	Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean	BU
09-10	Gilead Sciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
09-10	HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating	MT
09-09	Gilead Sciences, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 11:00 AM
09-08	Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead	MT
09-08	Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead	DJ
09-08	Gilead Sciences Opens Research Center At Foster City Headquarters	CI
09-08	Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines	BU
09-06	Gilead Sciences Announces FDA Approval for Bixlenvo as A Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv	CI
08-28	Gilead Sciences : Breaks Ground on New Biologics Facility as Part of $32 Billion U.S. R&D and Manufacturing Investment	PU
08-27	Gilead Sciences Wins FDA Approval for HIV Pill Bixlenvo	MT
08-27	US FDA approves Gilead's once-daily combination pill for HIV treatment	RE
08-27	U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens	BU
08-27	Gilead Sciences Announces FDA Approval Of Bixlenvo For Virologically Suppressed Adults With HIV	CI
08-27	FDA Approves Gilead Sciences' Bixlenvo for Certain Adults With HIV	DJ
08-26	Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences	BU